Observing a New Blood Test for Early Cancer Detection and Follow-Up
NCT05366881 · RecruitingThis study is looking at a new blood test to help find many types of cancer early. It includes cancers like breast, lung, and prostate. The goal is to see if this test can also find leftover cancer cells after treatment and detect a return of cancer before symptoms appear. Researchers want to help improve cancer care with this information.
Locations and contact
This trial is running at 17 locations in the United States. 16 of them are currently recruiting.
United States17 locations · 16 recruiting
- Allina Health Cancer InstituteMinneapolis, MinnesotaRecruiting
- Baptist (BHMCC)Memphis, TennesseeRecruiting
- Baptist CorbinCorbin, KentuckyRecruiting
- Baptist FloydNew Albany, IndianaRecruiting
- Baptist HardinElizabethtown, KentuckyRecruiting
- Baptist LexingtonLexington, KentuckyRecruiting
- City of HopeDuarte, CaliforniaRecruiting
- Cleveland ClinicCleveland, OhioRecruiting
- Elligo Health Research, Inc.Austin, TexasRecruiting
- Mayo ClinicRochester, MinnesotaRecruiting
- McLeod HealthFlorence, South CarolinaRecruiting
- Medical University of South CarolinaCharleston, South CarolinaRecruiting
- Miami Cancer InstituteMiami, FloridaRecruiting
- North Georgia Health SystemGainesville, GeorgiaRecruiting
- Oregon Health Sciences UniversityPortland, OregonRecruiting
- Vanderbilt-Ingram Cancer CenterNashville, TennesseeRecruiting
- Baptist PaducahPaducah, KentuckyWithdrawn
Who can join
This study is for adults aged 40 and older. People with newly diagnosed cancer or a recurrence of cancer are invited. Those without cancer in the past 5 years can also join. Pregnant women cannot participate. The trial team will confirm who is eligible.
What happens during the trial
Participants will be divided into two groups: one with people who have been newly diagnosed with cancer and another with people who do not have cancer. Everyone will provide a blood sample and have follow-ups to monitor their health. The study will track the ability of the blood test to detect cancer over two years.
The trial team
The trial is sponsored by Adela, Inc. Dr. Brian Rini from Vanderbilt-Ingram Cancer Center is the principal investigator leading the study.
Important dates
The study began on May 3, 2022, and is currently recruiting participants. It is expected to finish in March 2027.
Additional information
The trial's ID number is NCT05366881. This is an observational study looking at how well the blood test works. About 7,000 people will be included. The study is not focused on FDA-regulated drugs or devices.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →